Viewing data from:

SEVELAMER HYDROCHLORIDE

ANDA

SEVELAMER HYDROCHLORIDE | A218966 | NAVINTA LLC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: RENAGEL(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.7453

per ea

Lowest NADAC/Unit

$0.7453

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
70710205808SEVELAMER HCL 800 MG TABLET	$0.7453	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain10 active DMFs7 inactive

9 active API suppliers hold Drug Master Files for this ingredient.

SOLARA ACTIVE PHARMA SCIENCES LTDSEVELAMER HYDROCHLORIDE

DMF 211042007

LUPIN MANUFACTURING SOLUTIONS LTDSEVELAMER HYDROCHLORIDE

DMF 214882008

EMCURE PHARMACEUTICALS LTDSEVELAMER HYDROCHLORIDE (PROCESS-I)

DMF 220692008

FORMOSA LABORATORIES INCSEVELAMER HYDROCHLORIDE

DMF 226312009

EMCURE PHARMACEUTICALS LTDSEVELAMER HYDROCHLORIDE (PROCESS II)

DMF 248722011

SUN PHARMACEUTICAL INDUSTRIES LTDSEVELAMER HYDROCHLORIDE

DMF 254342011

NAVINTA LLCSEVELAMER HYDROCHLORIDE

DMF 279082014

APITORIA PHARMA PRIVATE LTDSEVELAMER HYDROCHLORIDE

DMF 310932016

AMI LIFESCIENCES PRIVATE LTDSEVELAMER HYDROCHLORIDE

DMF 380162023

HVL PHARMA UK LIMITEDSEVELAMER HYDROCHLORIDE

DMF 381982023

DOW CHEMICAL COInactiveSEVELAMER HYDROCHLORIDE

DMF 146952000

USV PRIVATE LTDInactiveSEVELAMER HYDROCHLORIDE

DMF 221132008

CHEMO IBERICA SAInactiveSEVELAMER HYDROCHLORIDE

DMF 223492008

DERIVADOS QUIMICOS SA FINE CHEMICALSInactiveSEVELAMER HYDROCHLORIDE

DMF 239392010

MYLAN LABORATORIES LTDInactiveSEVELAMER HYDROCHLORIDE

DMF 255792011

HETERO DRUGS LTDInactiveSEVELAMER HYDROCHLORIDE

DMF 261002012

CTX LIFE SCIENCES PVT LTDInactiveSEVELAMER HYDROCHLORIDE

DMF 274912013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 800MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Feb 3, 2025

No patent or exclusivity listings for this strength.